Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 18, Issue 2, 2000, Pages 405-411

  Lorusso, Vito ^a   Carpagnano, Francesco ^a   Frasci, Giuseppe ^a   Panza, Nicola ^a   Di Rienzo, Gaetano ^a   Cisternino, Mario Luigi ^a   Napoli, Gaetano ^a   Orlando, Silvio ^a   Cinieri, Saverio ^a   Brunetti, Cosimo ^a   Palazzo, Salvatore ^a   De Lena, Mario ^a  

^a Operative Unit of Medical OncologyOncology Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; NAVELBINE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN TISSUE; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE; THROMBOCYTOPENIA;

EID: 0033967260     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.2.405     Document Type: Article

References (24)

1. Grilli R, Oxman AD, Julian JA: Chemotherapy for advanced non-small cell lung cancer: How much benefit is enough? J Clin Oncol 11:1866-1872, 1993
2. Soquet PJ, Chauvin F, Boissel JP, et al: Polychemotherapy in advanced non small cell lung cancer: A meta-analysis. Lancet 342:19-21, 1993
3. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trial. BMJ 311:899-909, 1995
4. Ellis PA, Smith IE, Hardy JR, et al: Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small cell lung cancer. Br J Cancer 71:366-370, 1995
5. Cellerino R, Tummarello D, Piga A: Chemotherapy or not in advanced non-small cell lung cancer? Lung Cancer 6:99-109, 1990
6. Bakker W, van Oosterom AT, Aaronson NK, et al: Vindesine, cisplatin and bleomycin combination chemotherapy in non-small cell lung cancer: Survival and quality of life, Eur J Cancer Clin Oncol 22:963-970, 1986
7. Depierre A, Lemarie E, Dabouis G, et al: A phase II study of Navelbine (vinorelbine) in the treatment of non-small cell lung cancer. Am J Clin Oncol 14:115-119, 1991
8. Furuse K, Kubota K, Kawahara M, et al: Japan Navelbine Lung Cancer Study Group: A phase II study of navelbine, a new derivative of vinca alkaloid, for previously untreated non-small cell lung cancer. Lung Cancer 11:385-391, 1994
9. Le Chevalier T, Brisgand D, Douillard JY, et al: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: Results of a European multicenter trial including 612 patiens. J Clin Oncol 12:360-367, 1994
10. Depierre A, Chastang C, Quoix E, et al: Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: A randomised trial. Ann Oncol 5:37-42, 1994
11. Storniolo AM, Allerheiligen SRB, Pearce HL: Preclinical, pharmacology and phase I studies of gemcitabine. Semin Oncol 24:S7-2-S7-7, 1997 (suppl 7)
12. Abratt RP, Bezwoda WR, Falkson G, et al: Efficacy and safety profile of gemcitabine in non-small cell lung cancer: A phase II study. J Clin Oncol 12:1535-1540, 1994
13. Gatzeimer U, Sheperd FA, Le Chevalier T, et al: Activity of gemcitabine in patients with non-small cell lung cancer: A multicenter extended phase II study. Eur J Cancer 32A:243-248, 1996
14. Fossella FV, Lippman SM, Shin DJ, et al: Maximum tolerated dose defined for single agent gemcitabine: A phase I dose-escalation study in chemotherapy naive patients with advanced non-small cell lung cancer. J Clin Oncol 1:310-316, 1997
15. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, World Health Organization, 1979
16. Simon R: Confidence interval for reporting results of clinical trials. Ann Intern Med 105:429-435, 1986
17. Gehan EA: The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chron Dis 20:346-353, 1961
18. Ganz PA, Figlin RA, Haskell CM, et al: Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer: Does chemotherapy make a difference? Cancer 63:1271-1278, 1989
19. Woods RL, William CJ, Levi J, et al: A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br J Cancer 61:608-611, 1990
20. Thatcher N, Jayson G, Bradley B, et al: Gemcitabine: Symptomatic benefit in advanced non-small cell lung cancer. Semin Oncol 24:S8-6-S8-12, 1997 (suppl 8)
21. Anderson H. Lund B, Bach F, et al: A phase II study of weekly gemcitabine in advanced non-small cell lung cancer. J Clin Oncol 12:1281-1286, 1994
22. Anderson H, Thatcher N, Walling J, et al: Gemcitabine and palliation of symptoms in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 13:1821-1826, 1994
23. Gridelli C, Perrone F, Gallo C, et al: Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer: A two stage phase II study Eur J Cancer 33:392-397, 1997
24. Crinò L, Scagliotti G, Marangolo M, et al: Cisplatin gemcitabine combination in advanced non-small cell lung cancer: A phase II study. J Clin Oncol 15: 297-303, 1997